ストックスクリーナーアプリを入手
6.47
3.86%
-0.26
前日終値:
$6.73
開ける：
$6.8
24時間の取引高:
183.76K
Relative Volume:
0.88
時価総額：
$123.85M
収益：
-
当期純損益:
$-35.46M
株価収益率:
-15.34
EPS:
-0.4218
ネットキャッシュフロー:
$-34.00M
1週間 パフォーマンス:
+8.56%
1か月 パフォーマンス:
+65.05%
6か月 パフォーマンス:
-23.07%
1年 パフォーマンス:
-61.05%
1日の値動き範囲:
$6.25
$6.80
1週間の範囲:
$5.71
$6.95
52週間の値動き範囲:
$3.35
$20.55
Contineum Therapeutics Inc Stock (CTNM) Company Profile
名前
Contineum Therapeutics Inc
セクター
電話
(858) 333-5280
住所
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
CTNM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
6.47 | 163.77M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-20 | 開始されました | William Blair | Outperform |
| 2024-10-22 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-30 | 開始されました | Morgan Stanley | Overweight |
| 2024-04-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-04-30 | 開始されました | Stifel | Buy |
Contineum Therapeutics Inc (CTNM) 最新ニュース
Contineum Therapeutics Inc. stock trend forecastEntry Signal Generator with Risk Metrics - Newser
How Contineum Therapeutics Inc. stock reacts to Fed policy changesStock Trading Session Highlights and Summary - Newser
Published on: 2025-08-09 23:35:16 - Newser
Using portfolio simulators with Contineum Therapeutics Inc. includedCapital Growth Summary Over Five Years - Newser
Has Contineum Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewFree Smart Money Tracking Signal Generator - Newser
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
What data driven models say about Contineum Therapeutics Inc.’s futureFree Daily Momentum Screener With Alerts - Newser
William Blair Analysts Boost Earnings Estimates for CTNM - Defense World
Technical signs of recovery in Contineum Therapeutics Inc.Risk Aware Swing Trade Analysis Insights - Newser
Price momentum metrics for Contineum Therapeutics Inc. explainedConsistent Profit Signals with AI Models - Newser
Developing predictive dashboards with Contineum Therapeutics Inc. dataSupport and Resistance Zone Summary Chart - Newser
Will earnings trigger a reversal in Contineum Therapeutics Inc.Day Trading Setup and Momentum Analysis - Newser
Is Contineum Therapeutics Inc. stock entering bullish territorySupport and Resistance Zone Summary Chart - Newser
What makes Contineum Therapeutics Inc. stock price move sharplyReal Time Alert System for Market Moves - Newser
How high can Contineum Therapeutics Inc. stock goSmart Chart Forecasting with AI Algorithms - Newser
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 235.81%: Read This Before Placing a Bet - Yahoo Finance
Contineum (CTNM) Q2 R&D Jumps 78% - AOL.com
After losing 59% in the past year, Contineum Therapeutics, Inc. (NASDAQ:CTNM) institutional owners must be relieved by the recent gain - simplywall.st
How to use a screener to detect Contineum Therapeutics Inc. breakoutsEquity Performance Forecast Based on AI Models - Newser
Why Contineum Therapeutics Inc. stock attracts strong analyst attentionAI Based High Gain Watchlist Scanner Shared - metal.it
Strategies to average down on Contineum Therapeutics Inc.Daily Market Momentum Summary and Strategy - Newser
Earnings visualization tools for Contineum Therapeutics Inc.Chart Confirmation Setup with ROI Signals - Newser
Contineum reroutes pipeline, funneling cash from MS to lung disease as it eyes showdown with BMS - Fierce Biotech
RBC Cuts Price Target on Contineum Therapeutics to $25 From $31, Keeps Outperform, Speculative Risk - MarketScreener
Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones - BioSpace
Contineum (CTNM) Q2 R&D Jumps 78% - The Motley Fool
Applying Elliott Wave Theory to Contineum Therapeutics Inc.AI-Based Stock Behavior Forecast Engine - Newser
Contineum Therapeutics, Inc. SEC 10-Q Report - TradingView
Contineum Therapeutics Updates Clinical Development Milestones and Reports Q2 2025 Financial Results. - AInvest
Contineum Therapeutics Inc. Stock Performance After Earnings: Historical InsightsDaily Exit and Entry Price Prediction - Newser
What drives Contineum Therapeutics Inc. stock priceHigh-yield market plays - Jammu Links News
Long term hold vs stop loss in Contineum Therapeutics Inc.Technical Trend Forecast for Investors - Newser
What machine learning models say about Contineum Therapeutics Inc.Fundamental Analysis for Value Stock Selection - Newser
What analysts say about Contineum Therapeutics Inc. stockCapitalize on emerging trends for profits - Jammu Links News
Why is Contineum Therapeutics Inc. stock attracting strong analyst attentionTremendous growth opportunities - Jammu Links News
What are analysts’ price targets for Contineum Therapeutics Inc. in the next 12 monthsBuild wealth with high-performing stocks - Jammu Links News
What are the technical indicators suggesting about Contineum Therapeutics Inc.Free Consultation - Jammu Links News
Contineum Therapeutics Inc (CTNM) 財務データ
収益
当期純利益
現金流量
EPS
0.24%
3.39%
大文字化:
|
ボリューム (24 時間):